Toll Free: 1-888-928-9744

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 479 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Epithelial Ovarian Cancer - Pipeline Review, H1 2016', provides an overview of the Epithelial Ovarian Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects
- The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Epithelial Ovarian Cancer Overview 7 Therapeutics Development 8 Epithelial Ovarian Cancer - Therapeutics under Development by Companies 10 Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 14 Epithelial Ovarian Cancer - Pipeline Products Glance 15 Epithelial Ovarian Cancer - Products under Development by Companies 18 Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 23 Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 24 Epithelial Ovarian Cancer - Therapeutics Assessment 86 Drug Profiles 102 Epithelial Ovarian Cancer - Recent Pipeline Updates 294 Epithelial Ovarian Cancer - Dormant Projects 456 Epithelial Ovarian Cancer - Discontinued Products 460 Epithelial Ovarian Cancer - Product Development Milestones 461 Appendix 468
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2016 18 Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Development, H1 2016 27 Products under Development by Companies, H1 2016 28 Products under Development by Companies, H1 2016 (Contd..1) 29 Products under Development by Companies, H1 2016 (Contd..2) 30 Products under Development by Companies, H1 2016 (Contd..3) 31 Products under Development by Companies, H1 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H1 2016 33 Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2016 34 Epithelial Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 35 Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2016 36 Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 37 Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2016 38 Epithelial Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 39 Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2016 40 Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2016 41 Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 42 Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 43 Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016 44 Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2016 45 Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H1 2016 46 Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 47 Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 48 Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 49 Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H1 2016 50 Epithelial Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016 51 Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016 52 Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2016 53 Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2016 54 Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 55 Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2016 56 Epithelial Ovarian Cancer - Pipeline by Ignyta, Inc., H1 2016 57 Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2016 58 Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H1 2016 59 Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 60 Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2016 61 Epithelial Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H1 2016 62 Epithelial Ovarian Cancer - Pipeline by Mabion SA, H1 2016 63 Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 64 Epithelial Ovarian Cancer - Pipeline by MedImmune, LLC, H1 2016 65 Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2016 66 Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 67 Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 68 Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2016 69 Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016 70 Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2016 71 Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2016 72 Epithelial Ovarian Cancer - Pipeline by Oncolix, Inc., H1 2016 73 Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 74 Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 75 Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H1 2016 76 Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2016 77 Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2016 78 Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2016 79 Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 80 Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2016 81 Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 82 Epithelial Ovarian Cancer - Pipeline by Quest PharmaTech Inc., H1 2016 83 Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2016 84 Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2016 85 Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 86 Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2016 87 Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 88 Epithelial Ovarian Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 89 Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2016 90 Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 91 Epithelial Ovarian Cancer - Pipeline by Tyrogenex, Inc., H1 2016 92 Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 93 Epithelial Ovarian Cancer - Pipeline by ViiV Healthcare Limited, H1 2016 94 Epithelial Ovarian Cancer - Pipeline by Vyriad, H1 2016 95 Assessment by Monotherapy Products, H1 2016 96 Number of Products by Stage and Target, H1 2016 98 Number of Products by Stage and Mechanism of Action, H1 2016 104 Number of Products by Stage and Route of Administration, H1 2016 109 Number of Products by Stage and Molecule Type, H1 2016 111 Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2016 304 Epithelial Ovarian Cancer - Dormant Projects, H1 2016 466 Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2016 467 Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H1 2016 468 Epithelial Ovarian Cancer - Dormant Projects (Contd..3), H1 2016 469 Epithelial Ovarian Cancer - Discontinued Products, H1 2016 470


List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H1 2016 18 Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Products, H1 2016 27 Assessment by Monotherapy Products, H1 2016 96 Number of Products by Top 10 Targets, H1 2016 97 Number of Products by Stage and Top 10 Targets, H1 2016 97 Number of Products by Top 10 Mechanism of Actions, H1 2016 103 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 103 Number of Products by Top 10 Routes of Administration, H1 2016 108 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 108 Number of Products by Top 10 Molecule Types, H1 2016 110 Number of Products by Stage and Top 10 Molecule Types, H1 2016 110

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify